2022 What’s Next for Biotechnology Innovation? - Emerging Technologies, Pipeline and Clinical Trials Review, Competitive SWOT Analysis, Partnering Deals

2022 What’s Next for Biotechnology Innovation? - Emerging Technologies, Pipeline and Clinical Trials Review, Competitive SWOT Analysis, Partnering Deals

This report is available by section, and can be customized to specific objectives, information needs and budget. The series includes current assessments of more than 1,000 companies worldwide. Depending on the company’s business nature and structure, the assessments include all or some of the following analyses: Organization and Management, Acquisitions and Divestitures, Facilities and Employees, Research and Development, Technological Know-How, Key Products, Marketing Capabilities, Financial Results, Strengths and Weaknesses, and Strategic Directions.

The report analyzes the following companies:

Actavis
Amgen
Biogen
Bristol-Myers Squibb
Gilead Sciences
Merck
Novo Nordisk
Roche
Shire
Teva

The report provides significant competitor information, analysis and insight critical to the development and implementation of effective marketing and R&D programs.

In the dynamic and fragmented Biotechnology industry, besieged by intense competition and rapid change of technological innovations, the ability to anticipate new product introductions and marketing strategies is particularly important...and can spell the difference between success and failure.

The report’s objectives include:

- To assist potential market entrants in evaluating prospective acquisitions and joint venture candidates.
- To complement organizations’ internal competitor information gathering efforts with strategic analysis, data interpretation and insight.

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.